RASGenix is a leading oncology research company specializing in the development of therapies for cancers linked to mutations in the RAS gene, which are responsible for approximately 20 percent of cancers, including lung, colorectal, and pancreatic cancers. Founded by experts with international experience, RASGenix is distinguished by its ability to provide customized, high-quality preclinical solutions to help pharmaceutical companies discover new drugs quickly and efficiently.
RASGenix provides advanced preclinical services using complex genetic models to compare and evaluate different RAS mutations, increasing the likelihood of successful therapies in development. With flexible packages to suit the needs of companies of all sizes, RASGenix is the ideal partner to explore new therapeutic strategies and accelerate the path to effective treatments for RAS-dependent cancers.